Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
NCT06250972

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Led by Fudan University · Updated on 2025-08-07

210

Participants Needed

1

Research Sites

206 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy of chemotherapy plus radiotherapy to patients with CA19-9-elevated Advanced Pancreatic Cancer who are not refractory to chemotherapy.

CONDITIONS

Official Title

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand and willing to sign informed consent
  • Age between 18 and 80 years
  • ECOG performance status 0 to 2
  • Confirmed advanced pancreatic adenocarcinoma by histology or cytology
  • Not resistant to previous chemotherapy and no prior radiotherapy
  • Locally advanced pancreatic cancer
  • Baseline serum CA19-9 greater than 37 U/mL, with normal CA19-9 after chemotherapy
  • At least one measurable tumor lesion per RECIST criteria
  • Expected survival of at least 3 months
  • Adequate organ function based on lab tests
  • Agree to use contraception if of childbearing potential
Not Eligible

You will not qualify if you...

  • Pregnant or nursing women
  • Primary pancreatic cancer
  • Baseline serum CA19-9 37 U/mL or below
  • Non-adenocarcinoma pancreatic cancer confirmed by pathology
  • Digestive tract inflammation such as pancreatitis, cholecystitis, or cholangitis
  • Severe or uncontrolled diseases affecting study compliance or results
  • Renal insufficiency or dialysis
  • Other serious illnesses affecting treatment safety
  • Allergy to oxaliplatin or other chemotherapy drugs
  • Unwilling or unable to follow study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

Loading map...

Research Team

Y

Ying Yang, MD

CONTACT

G

Guopei Luo, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer | DecenTrialz